Global Bio-India (GBI) 2024 opened in New Delhi on 12th September as a much bigger event as compared to 2023 with participation from 30+ countries, 500+ exhibitors, 5000+ delegates, 1000+ startups, B2B, B2G, G2G meetings and much more.

Addressing the inaugural ceremony of the Global Bio India Conference, Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh said “There are a billion reasons to invest in India, the reasons being India has 60% share of global vaccine production, it has the 2^nd highest number of US FDA approved manufacturing plants outside the US. Opportunities for investments are available in Bio-Pharma, Bio-Agri, Bio-Industrial, Bio-energy, Bio-Services and Med-Tech.”

The event also saw the launch of the BioEconomy report 2024, prepared for 'Make In India Facilitation Cell for Biotechnology' of Biotechnology Industry Research Assistance Council (BIRAC), by Association of Biotechnology Led Enterprises (ABLE).

The event also witnessed the official launch of the BioE3 policy recently approved by the government. The goal of the Policy is to fast-track innovation-to-technology in a sustainable manner by weaving together fragmented activities under the umbrella of biomanufacturing and to incentivise concrete options to build a sustainable future.

BIRAC signed Letter of Intent with 9 leading international organisations in biotechnology namely- United States Pharmacopeial Convention (USP); UK Research and Innovation (UKRI); Danaher India; Mauritius Institute of Biotechnology (MIBL); La Trobe University; Blockchain for Impact (BFI); US-India Strategic Partnership Forum (USISPF); IBioM (Indian Biotech MSME and Startup Foundation); and Bharat Startup and Innovation Society (BSIS)- Bharat Startup Festival.

Further, special booklets namely BIRAC Compendium of Products and Technologies 2024, Insights into BIRAC Equity Fund and Amrit Grand Challenge JanCARE Innovations Report were also launched during the inaugural session of GBI 2024.